THE APEX TIMES
The company lifted its annual profit forecast as performance for its blood thinner Eliquis remained solid, according to a report citing Pfizer’s latest guidance update.
Pfizer increased its full-year profit forecast, pointing to demand momentum for Eliquis, its widely used oral blood thinner, as a key driver behind the improved outlook. The update was reported by Yahoo Finance on November 3, 2026.
Eliquis (apixaban) is an anticoagulant, a class of medicine designed to help reduce the risk of blood clots. For Pfizer, Eliquis has been a central contributor to revenue and earnings, and the company’s decision to raise guidance suggests that billing and patient demand have remained resilient.
While the report focuses on the direction of Pfizer’s forecast, it does not provide, in the material available here, the specific revised profit figure, the prior forecast level, or the precise assumptions the company used. It also does not break out whether the change reflects updated expectations for unit growth, pricing, reimbursement trends, or foreign exchange impacts.
The news arrives at a time when major drugmakers routinely adjust guidance to reflect the evolving mix of new prescriptions, treatment switching, and category-level competitiveness. For Pfizer, Eliquis demand has been closely watched because even incremental changes in prescribing can affect the trajectory of revenue and profitability across multiple quarters.
In general terms, profit guidance raises can announcement confidence that underlying operating performance is tracking above earlier expectations. However, investors and analysts often look closely at whether upgrades are broad-based across the portfolio or concentrated in a single franchise, especially when that franchise is a major share of earnings.
Pfizer did not disclose in the available report whether the forecast increase is tied solely to Eliquis or whether other lines of business, cost initiatives, or non-operating items contributed. The update also does not detail any change to the company’s regulatory or manufacturing risk outlook, which can matter for major medicines with large global usage.
What to watch next is whether Pfizer offers additional detail in forthcoming materials, such as its next quarterly results or a formal earnings release that includes the updated profit range and supporting drivers. Market participants will also likely monitor any indications of demand trends for Eliquis, including prescription volumes and competitive dynamics in anticoagulation therapy.
U.S. index futures pointed to a mixed start as investors weighed a busy earnings backdrop, with attention shifting toward the next round of major chip updates and upcoming political catalysts.
Leidos Holdings Inc. (NYSE:LDOS) reported third-quarter adjusted earnings above Wall Street expectations, citing improved operating profitability and strong cash generation, while acknowledging that revenue did not meet the forecast.
Chord, an AI-native data platform for commerce, said it is buying Zenlytic, positioning the combined offering for enterprise business intelligence and naming Verizon among new customer logos cited in the expansion.
The companies say the agreement aims to accelerate quantum technology development tied to transportation, sustainability, and future mobility applications, while providing few technical or financial details publicly.
The consulting firm said the new Deloitte Oracle business group is meant to unify its Oracle-focused work across key enterprise areas, from AI-enabled modernization to applications and cloud migrations.
The expense and travel management platform says the agreement is designed to help companies simplify how they manage corporate cards and related spending.
A public clash between investor Michael Burry and Palantir CEO Alex Karp has become a yardstick for how quickly markets can flip on disruptive, high-expectation software stories. One year on, the debate is less about who was right in tone and more about whether the valuation can ever look “earned.”
A recent quarter topped expectations, yet the broader housing market remains stuck near historical lows and the stock is still down for the year, keeping investors focused on how much demand can normalize.
A Yahoo Finance discussion around Apple’s most recent quarterly earnings revisited the question of whether the company “sat out” parts of the artificial intelligence race, as analysts and investors pressure tech leaders for faster product and platform shifts.
The Walt Disney Company says the series, adapted from a NAVER Webtoon with billions of views, will launch on Tuesday, November 3 instead of Thursday, November 4, with staggered weekly releases beginning November 11.
